TY - JOUR
T1 - Antileishmanial and Antiplasmodial Activities of Secondary Metabolites from the Root of Antrocaryon klaineanum Pierre (Anacardiaceae)
AU - Amang à Ngnoung, Gabrielle Ange
AU - Sidjui, Lazare S.
AU - Leutcha, Peron B.
AU - Nganso Ditchou, Yves O.
AU - Tchokouaha, Lauve R.Y.
AU - Herbette, Gaëtan
AU - Baghdikian, Beatrice
AU - Kowa, Theodora K.
AU - Soh, Desire
AU - Kemzeu, Raoul
AU - Poka, Madan
AU - Demana, Patrick H.
AU - Siwe Noundou, Xavier
AU - Tchinda, Alembert T.
AU - Fekam Boyom, Fabrice
AU - Lannang, Alain M.
AU - Nyassé, Barthélemy
N1 - Funding Information:
The authors are gratefully acknowledge the University of Maroua, the Institute for Medical Research and Medicinal Plants Studies (IMPM), the Laboratory of Phytobiochemistry and Medicinal Plant Studies, Antimicrobial and Biocontrol Agents Unit at the Department of biochemistry of the University of Yaoundé I in Cameroon for biological tests, the Aix-Marseille Univ, CNRS, Centrale Marseille, FSCM, Spectropole, Campus de St Jérôme-Service 511, 13397 Marseille, France for spectroscopic analysis, the Yaoundé-Bielefield Graduate School through YaBiNaPA for their facilities. FFB is gratefully thanking the Grand Challenges Africa (GCA) program [GCA/DD/rnd3/006] for supporting the Biological activities. GCA is a program of the African Academy of Sciences (AAS) implemented through the Alliance for Accelerating Excellence in Science in Africa (AESA) platform, an initiative of the AAS and the African Union Development Agency (AUDA-NEPAD). For this work, GCA is supported by the AAS, Bill & Melinda Gates Foundation (BMGF), Medicines for Malaria Venture (MMV), and Drug Discovery and Development Centre of University of Cape Town (H3D).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - Antrocaryon klaineanum is traditionally used for the treatment of back pain, malaria, female sterility, chlamydiae infections, liver diseases, wounds, and hemorrhoid. This work aimed at investigating the bioactive compounds with antileishmanial and antiplasmodial activities from A. klaineanum. An unreported glucocerebroside antroklaicerebroside (1) together with five known compounds (2–6) were isolated from the root barks of Antrocaryon klaineanum using chromatographic techniques. The NMR, MS, and IR spectroscopic data in association with previous literature were used for the characterization of all the isolated compounds. Compounds 1–4 are reported for the first time from A. klaineanum. The methanol crude extract (AK-MeOH), the n-hexane fraction (AK-Hex), the dichloromethane fraction (AK-DCM), the ethyl acetate fraction (AK-EtOAc), and compounds 1–6 were all evaluated for their antiparasitic effects against Plasmodium falciparum strains susceptible to chloroquine (3D7), resistant to chloroquine (Dd2), and promastigotes of Leishmania donovani (MHOM/SD/62/1S). The AK-Hex, AK-EtOAc, AK-MeOH, and compound 2 were strongly active against Dd2 strain with IC50 ranging from 2.78 ± 0.06 to 9.30 ± 0.29 µg/mL. Particularly, AK-MeOH was the most active—more than the reference drugs used—with an IC50 of 2.78 ± 0.06 µg/mL. The AK-EtOAc as well as all the tested compounds showed strong antileishmanial activities with IC50 ranging from 4.80 ± 0.13 to 9.14 ± 0.96 µg/mL.
AB - Antrocaryon klaineanum is traditionally used for the treatment of back pain, malaria, female sterility, chlamydiae infections, liver diseases, wounds, and hemorrhoid. This work aimed at investigating the bioactive compounds with antileishmanial and antiplasmodial activities from A. klaineanum. An unreported glucocerebroside antroklaicerebroside (1) together with five known compounds (2–6) were isolated from the root barks of Antrocaryon klaineanum using chromatographic techniques. The NMR, MS, and IR spectroscopic data in association with previous literature were used for the characterization of all the isolated compounds. Compounds 1–4 are reported for the first time from A. klaineanum. The methanol crude extract (AK-MeOH), the n-hexane fraction (AK-Hex), the dichloromethane fraction (AK-DCM), the ethyl acetate fraction (AK-EtOAc), and compounds 1–6 were all evaluated for their antiparasitic effects against Plasmodium falciparum strains susceptible to chloroquine (3D7), resistant to chloroquine (Dd2), and promastigotes of Leishmania donovani (MHOM/SD/62/1S). The AK-Hex, AK-EtOAc, AK-MeOH, and compound 2 were strongly active against Dd2 strain with IC50 ranging from 2.78 ± 0.06 to 9.30 ± 0.29 µg/mL. Particularly, AK-MeOH was the most active—more than the reference drugs used—with an IC50 of 2.78 ± 0.06 µg/mL. The AK-EtOAc as well as all the tested compounds showed strong antileishmanial activities with IC50 ranging from 4.80 ± 0.13 to 9.14 ± 0.96 µg/mL.
KW - Antrocaryon klaineanum
KW - anacardiaceae
KW - antileishmanial activity
KW - antiplasmodial activity
KW - cerebroside
UR - http://www.scopus.com/inward/record.url?scp=85151107656&partnerID=8YFLogxK
U2 - 10.3390/molecules28062730
DO - 10.3390/molecules28062730
M3 - Article
C2 - 36985700
AN - SCOPUS:85151107656
SN - 1420-3049
VL - 28
JO - Molecules
JF - Molecules
IS - 6
M1 - 2730
ER -
